Justin M Darrah1,2, Alex F Herrera3. 1. Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA, 91010, USA. 2. Department of Hematology and Oncology, Harbor-UCLA Medical Center, Torrance, CA, USA. 3. Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA, 91010, USA. aherrera@coh.org.
Abstract
PURPOSE OF REVIEW: The use of circulating tumor DNA (ctDNA) for the purposes of diagnosis, prognosis, assessment of treatment response, and monitoring for relapse is a new and developing field in lymphoma. This review aims to summarize many of the most recent advances in ctDNA applications. RECENT FINDINGS: Recent studies have demonstrated the use of ctDNA assessment across many lymphoma subtypes including diffuse large B-cell lymphoma, follicular lymphoma, Hodgkin lymphoma, and T-cell lymphoma. In addition, many novel applications of ctDNA assessment have been described such as the development of new prognostic models, investigation of clonal evolution and heterogeneity, early assessment of treatment response, and prediction of response to targeted therapy as a form of personalized medicine. The use of ctDNA has been shown to be feasible across many lymphoma subtypes and has shown significant promise for several new applications. Additional studies will be needed to validate these findings prior to routine use in clinical practice.
PURPOSE OF REVIEW: The use of circulating tumor DNA (ctDNA) for the purposes of diagnosis, prognosis, assessment of treatment response, and monitoring for relapse is a new and developing field in lymphoma. This review aims to summarize many of the most recent advances in ctDNA applications. RECENT FINDINGS: Recent studies have demonstrated the use of ctDNA assessment across many lymphoma subtypes including diffuse large B-cell lymphoma, follicular lymphoma, Hodgkin lymphoma, and T-cell lymphoma. In addition, many novel applications of ctDNA assessment have been described such as the development of new prognostic models, investigation of clonal evolution and heterogeneity, early assessment of treatment response, and prediction of response to targeted therapy as a form of personalized medicine. The use of ctDNA has been shown to be feasible across many lymphoma subtypes and has shown significant promise for several new applications. Additional studies will be needed to validate these findings prior to routine use in clinical practice.
Authors: V H J van der Velden; A Hochhaus; G Cazzaniga; T Szczepanski; J Gabert; J J M van Dongen Journal: Leukemia Date: 2003-06 Impact factor: 11.528
Authors: Mark Roschewski; Kieron Dunleavy; Stefania Pittaluga; Martin Moorhead; Francois Pepin; Katherine Kong; Margaret Shovlin; Elaine S Jaffe; Louis M Staudt; Catherine Lai; Seth M Steinberg; Clara C Chen; Jianbiao Zheng; Thomas D Willis; Malek Faham; Wyndham H Wilson Journal: Lancet Oncol Date: 2015-04-01 Impact factor: 41.316
Authors: Sarit E Assouline; Torsten Holm Nielsen; Stephen Yu; Miguel Alcaide; Lauren Chong; David MacDonald; Axel Tosikyan; Vishal Kukreti; Abbas Kezouh; Tina Petrogiannis-Haliotis; Marco Albuquerque; Daniel Fornika; Sepideh Alamouti; Remi Froment; Celia M T Greenwood; Kathleen Klein Oros; Errol Camglioglu; Ayushi Sharma; Rosa Christodoulopoulos; Caroline Rousseau; Nathalie Johnson; Michael Crump; Ryan D Morin; Koren K Mann Journal: Blood Date: 2016-05-10 Impact factor: 22.113
Authors: Alex F Herrera; Haesook T Kim; Katherine A Kong; Malek Faham; Heather Sun; Aliyah R Sohani; Edwin P Alyea; Victoria E Carlton; Yi-Bin Chen; Corey S Cutler; Vincent T Ho; John Koreth; Chitra Kotwaliwale; Sarah Nikiforow; Jerome Ritz; Scott J Rodig; Robert J Soiffer; Joseph H Antin; Philippe Armand Journal: Br J Haematol Date: 2016-10-06 Impact factor: 6.998
Authors: S Hohaus; M Giachelia; G Massini; G Mansueto; B Vannata; V Bozzoli; M Criscuolo; F D'Alò; M Martini; L M Larocca; M T Voso; G Leone Journal: Ann Oncol Date: 2009-05-22 Impact factor: 32.976
Authors: Florian Scherer; David M Kurtz; Aaron M Newman; Henning Stehr; Alexander F M Craig; Mohammad Shahrokh Esfahani; Alexander F Lovejoy; Jacob J Chabon; Daniel M Klass; Chih Long Liu; Li Zhou; Cynthia Glover; Brendan C Visser; George A Poultsides; Ranjana H Advani; Lauren S Maeda; Neel K Gupta; Ronald Levy; Robert S Ohgami; Christian A Kunder; Maximilian Diehn; Ash A Alizadeh Journal: Sci Transl Med Date: 2016-11-09 Impact factor: 17.956
Authors: Simon Bomken; Jutte van der Werff Ten Bosch; Andishe Attarbaschi; Chris M Bacon; Arndt Borkhardt; Kaan Boztug; Ute Fischer; Fabian Hauck; Roland P Kuiper; Tim Lammens; Jan Loeffen; Bénédicte Neven; Qiang Pan-Hammarström; Isabella Quinti; Markus G Seidel; Klaus Warnatz; Claudia Wehr; Arjan C Lankester; Andrew R Gennery Journal: Front Immunol Date: 2018-12-12 Impact factor: 7.561